The FDA's DHCoE plays a pivotal role in the oversight and advancement of digital health technologies, including Virtual Reality (VR) and Augmented Reality (AR) medical devices and digital therapeutics. Its primary purpose is to streamline the regulatory pathways for these innovative technologies, ensuring their safety, effectiveness, and quality for clinical applications. The scope covers a wide range of uses, from diagnosis and treatment to rehabilitation and disease management, across various medical specialties.